



The Schelin Catheter™ introduced in conjunction with yet another treatment method

This week, Schelin Catheter™ was successfully used at Guy's Hospital in London, UK for yet another minimally invasive method of treating benign prostatic hyperplasia (BPE). Two patients who underwent treatments with UroLift® System (Registered trademark of Teleflex® and its subsidiary NeoTract® Inc.) received intraprostatic local anesthesia through ProstaLund's injection device prior to treatments.

The Schelin Catheter™ has been used for many years as standard before thermotherapy with ProstaLund's own method CoreTherm®. Then local anesthesia with adrenaline in the prostate is administered with the help of the catheter, which contributes to a substantial painless treatment and a reduced blood flow in the prostate, which in turn has shortened the thermotherapy to today's approximately 10-15 minutes. With the Schelin Catheter™, the prostate can be effectively anesthetized in an easy and sterile way.

"Earlier this year, there has been world premieres for the use of the Schelin Catheter™ in conjunction with water vapor therapy and green laser surgery. The fact that we have now shown that the Schelin Catheter™ can be used for another method shows the potential that our product possesses. The great interest in our product is due to the fact that the clinic can move prostate treatments from resource-intensive operating theaters to an outpatient setting and thus make great savings in the form of human resources, beds and money. At the same time, the patient does not need to have general anesthesia or be sedated and can thus go home immediately after treatment.", says CEO Johan Wennerholm in a comment.

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com



PRESS RELEASE
01 December 2022 10:00:00 CET

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

Attachments

The Schelin Catheter™ introduced in conjunction with yet another treatment method